DiaMedica granted clearance for Phase II diabetes study

DM-99 is a biological product with a well established safety profile that is being studied by DiaMedica for a novel use as a treatment for type 2 diabetes. The product has demonstrated the ability to positively impact glucose metabolism in animal models.

Karl-Gunnar Hidinger, president of DiaMedica, said: “This will be a double-blind crossover study in 20 diabetic patients that will measure the change in glucose and insulin levels after a meal. In this manner the variability between patients is minimized because each patient crossing over between placebo and DM-99 treatment in effect serves as its own control. The results of this study will give an indication as to how well DM-99 works at controlling blood glucose levels in a type 2 diabetic population and thus guide us into the next stage of clinical development”.